Nivolumab

Verified

Overview

Normally, your immune system helps defend against internal threats, such as cancer, using specialized immune cells called T cells. Some types of cancer cells present a protein called PD-L1, which interacts with the PD-1 receptor on your T cells. This can deactivate your T cells and prevent them from recognizing and attacking the cancer. Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

SparkCures ID 99
Developed By Bristol-Myers Squibb
Generic Name Nivolumab
Additional Names BMS-936558
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified
Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified
Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment i...
View Trial
Smoldering Myeloma

The following is a listing of clinical trials for patients with Smoldering Myeloma.

Nivolumab + Lenalidomide + Dexamethasone In High-Risk Smoldering Multiple Myeloma
View Trial
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.

SparkCures Verified

SparkCures is working closely with Bristol-Myers Squibb to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners